Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

BGM vs ESPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESPR Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

ESPR Overall Winner 6-Pillar Tally: BGM 0 – 6 ESPR Matrix Metrics: BGM 3 – 7 ESPR

As of Nov 19, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin).

  • Growth vs. Quality Trade-Off: ESPR earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. BGM 59.6/100 HOLD) and 1.86β · 6% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs ESPR
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
ESPR NASDAQ Head-to-Head Winner
Esperion Therapeutics, Inc.
Pharmaceutical Preparations
$3.18
-0.31% 1D
Market Cap $822.0M
TTM Revenue $418M
Forward P/E 10.9x
Beta / 30D Vol 1.86β · 6% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 64.0 Flow 70.0 Mom 70.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 64
RSI-14: 63.5 · SMA20: $3.16 · SMA50: $3.10

6-Pillar Scorecard Institutional Category Breakdown (BGM 0 – 6 ESPR)

Columns: Metric · BGM · ESPR
1. Valuation Multiples ESPR
Forward P/E N/M 10.9x
Trailing P/E N/M 4.6x
PEG Ratio N/M N/M
EV / Revenue 2.3x 2.2x
2. Growth & Scale ESPR
Revenue Growth (YoY) +69.8% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $48M $418M
Market Cap $108.6M $822.0M
3. Profitability & Quality ESPR
Gross Margin 16.9% 57.8%
Operating Margin -23.4% -8.2%
Net Profit Margin -44.2% -1.8%
Return on Equity (ROE) -7.4% -260.8%
4. Balance Sheet & Cash Flow ESPR
Cash Generation (TTM) -$9.2M EBITDA -$18M
Cash Flow Margin -19.3% EBITDA Mgn -4.4%
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $96M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESPR
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 12.5% (9th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ESPR
OpEx & R&D Intensity 40.3% of Rev ($19M) 66.0% of Rev ($276M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (3) vs ESPR (7)
Institutional Metric BGM ESPR Criterion Row Edge
Market Capitalization
Scale
$108.6M $822.0M Larger Scale ESPR
Trailing P/E Ratio
Valuation
N/M 4.6x Lower Multiple ESPR
Forward P/E Ratio
Valuation
N/M 10.9x Lower Multiple ESPR
Revenue Growth (YoY)
Growth
+69.8% +23.2% Higher Growth BGM
Operating Margin (TTM)
Profitability
-23.4% -8.2% Higher Margin ESPR
Net Profit Margin
Profitability
-44.2% -1.8% Higher Margin ESPR
Return on Equity (ROE)
Capital Efficiency
-7.4% -260.8% Higher ROE BGM
52-Week Range Position
Momentum
74% ($0–$11) 68% ($1–$4) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol 1.86β · 6% Vol Lower Realized Risk ESPR
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite ESPR
Trailing 12M Revenue (USD)
Operating Scale
$48M $418M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% 57.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) -$18M ($96M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ESPR +2.77 pp
BGM: -1.5% · ESPR: +1.27%
3M Horizon ESPR +36.36 pp
BGM: +9.51% · ESPR: +45.87%
6M Horizon ESPR +74.38 pp
BGM: -91.57% · ESPR: -17.19%
1Y Horizon ESPR +116.1 pp
BGM: -96.55% · ESPR: +19.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs ESPR. Trailing 12-month operating profitability (BGM -23.4% vs ESPR -8.2%) and valuation multiples (BGM N/M vs ESPR 10.9x Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
ESPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$418M
Gross Margin57.8%
Op. Margin-8.2%
ROE / Fwd P/E-260.8% · 10.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ESPR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 12.5%
IV Percentile 9th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ESPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
ESPR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $822.0M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 66.0% of Rev ($276M)
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs ESPR Key Questions & Quantitative Answers

As of Nov 19, 2026, Esperion Therapeutics, Inc. (ESPR) is the stronger overall head-to-head candidate over BGM Group Ltd. Class A (BGM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BGM carries a Unified Composite Score of 59.6/100 (HOLD) at $8.00 (N/M Forward P/E, -23.4% operating margin), whereas ESPR carries 60.0/100 (BUY) at $3.18 (10.9x Forward P/E, -8.2% operating margin). Growth vs. Quality Trade-Off: ESPR earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. BGM 59.6/100 HOLD) and 1.86β · 6% Vol risk profile, whereas BGM leads top-line expansion (+69.8% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

ESPR leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with ESPR at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $418M TTM revenue (57.8% gross margin, -8.2% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $418M for ESPR. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 66.0% of Rev ($276M) (0 disclosures) for ESPR.

ESPR screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas ESPR trades at 10.9x Forward P/E, 4.6x Trailing P/E, N/M PEG, and 2.2x EV/Revenue (-4.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus ESPR (-260.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, ESPR carries 12.5% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.86β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.